Compare NTZ & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTZ | LEXX |
|---|---|---|
| Founded | 1959 | 2004 |
| Country | Italy | Canada |
| Employees | N/A | 7 |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.0M | 16.5M |
| IPO Year | 1998 | N/A |
| Metric | NTZ | LEXX |
|---|---|---|
| Price | $1.55 | $0.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 3.2K | ★ 60.9K |
| Earning Date | 04-13-2023 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $601.47 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.50 | $0.46 |
| 52 Week High | $3.95 | $1.55 |
| Indicator | NTZ | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 32.51 | 45.70 |
| Support Level | $1.50 | $0.56 |
| Resistance Level | $2.00 | $0.70 |
| Average True Range (ATR) | 0.07 | 0.06 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 12.00 | 25.85 |
Natuzzi SpA is an Italian firm that designs, manufactures, and sells contemporary and traditional leather and fabric-upholstered furniture. Its product portfolio includes sofas, loveseats, armchairs, sectional furniture, motion furniture, sofa beds, living room furnishings, and accessories. The company markets its products under several brands such as Natuzzi Italia, Private Label, and Natuzzi Editions. The Group operates in two operating segments, the Natuzzi brand and Private label. The Natuzzi brand segment includes net sales from the Natuzzi Italia, Natuzzi Editions, and Divani&Divani by Natuzzi product lines. Geographically, it derives a majority of its revenue from the United States of America and also has an international presence in Italy, Spain, the UK, China, and Other countries.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.